✨ Unlock Unlimited Data Exports & Disclosures Access with Tracenable Pro. Learn More →

Sumitomo Pharma Co Ltd

Common Name
Sumitomo Pharma
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
3,832
Ticker
4506
Exchange
TOKYO STOCK EXCHANGE
Description
Sumitomo Pharma Co., Ltd. is a prominent player in the global biopharmaceutical industry, primarily focused on the development, manufacturing, and marketing of pharmaceuticals. The company engages in ...

Sumitomo Pharma's GHG Emissions Data Preview

In 2024, Sumitomo Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Sumitomo Pharma has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Location-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Total Scope 3
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Sumitomo Pharma’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2019, and revenue-based intensity metrics for each scope.
Unrestricted Access to Data and Sources
pro
Remove manual data sourcing from your workflow. Upgrade to Tracenable Pro for unrestricted access to datasets and disclosures across 8,500+ companies with over 10 years of historical coverage.
Download complete datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace values back to original sources
Formats Included
Excel
CSV
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=4506&reporting_period=2024"

Verified Sources Behind Sumitomo Pharma’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sumitomo Pharma’s data sources below and access millions more through our Disclosure Search.

a. Sumitomo Pharma's ESG Data Spreadsheet 2025
b. Sumitomo Pharma's Integrated Report 2022

Insights into Sumitomo Pharma's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma amounted to 61,239 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma decreased by 13.11%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Sumitomo Pharma's Scope 1 Emissions Over Time

20192020202120222023202407 k14 k21 k28 ktCO2e+2%+10%+30%-3%-15%
  • Total Scope 1
  • Year-over-Year Change

What are Sumitomo Pharma's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Sumitomo Pharma were 23,101 metric tons of CO₂ equivalent (tCO₂e).a

Has Sumitomo Pharma reduced its Scope 1 emissions over time?

Since 2019, Sumitomo Pharma's Scope 1 emissions have increased by 20.19%, reflecting a rising long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Sumitomo Pharma's Scope 1 emissions decreased by 14.73%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Sumitomo Pharma's Scope 2 emissions?

In 2024, Sumitomo Pharma reported Scope 2 greenhouse gas (GHG) emissions of 23,157 tCO₂e using the market-based method and 38,138 tCO₂e using the location-based method.a

Has Sumitomo Pharma reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Sumitomo Pharma's Scope 2 emissions (Location-Based) fell by 12.1% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a

What methodology does Sumitomo Pharma use for Scope 2 reporting?

In 2024, Sumitomo Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a

Sumitomo Pharma's Scope 2 Emissions Over Time

201920202021202220232024015 k30 k45 k60 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Sumitomo Pharma's Value Chain Emissions

In 2024, Sumitomo Pharma reported 268,271 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Sumitomo Pharma includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Sumitomo Pharma's Scope 3 Emissions Over Time

20212022202320240100 k200 k300 k400 ktCO2e-4%-3%-25%
  • Total Scope 3
  • Year-over-Year Change

What are Sumitomo Pharma's Scope 3 emissions?

In 2024, Sumitomo Pharma reported total Scope 3 emissions of 268,271 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 98.53% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.47% came from downstream activities like product use, distribution, and end-of-life treatment.a

Compared to the previous year (2023), Sumitomo Pharma's Scope 3 emissions decreased by 24.58%, highlighting the company's efforts to lower indirect emissions from its value chain.a

What categories of Scope 3 emissions does Sumitomo Pharma disclose?

In 2024, Sumitomo Pharma reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Sumitomo Pharma's Scope 3 emissions?

In 2024, the largest contributors to Sumitomo Pharma's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 229,764 tCO₂e (85.65%)
  • Capital Goods (Cat. 2): 14,740 tCO₂e (5.49%)
  • Fuel- and Energy-Related Services (Cat. 3): 12,613 tCO₂e (4.7%)

Sumitomo Pharma's Scope 3 Emissions by Categories

Fuel- andEnergy-RelatedServices (Cat. 3)(4.7%)Purchased Goods andServices (Cat. 1)(85.6%)Capital Goods(Cat. 2)(5.5%)

Insights into Sumitomo Pharma’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Sumitomo Pharma reported Scope 1 greenhouse gas (GHG) emissions of 23,101 tCO₂e and total revenues of USD 2,077 millions. This translates into an emissions intensity of 11.12 tCO₂e per millions USD.a

Sumitomo Pharma's Scope 1 Emissions Intensity Compared to Peers

102002,00050,0001,000,000Scope 1 Emissions (tCO2e)201001,00010,000100,000Revenues (Millions of USD)MNMEisaiYear: 2024Scope 1: 45,666 tCO2eRevenue: $M 4,898Scope 1 Intensity: 9.32 tCO2e/$MHisamitsu PharmaceuticalYear: 2022Scope 1: 7,862 tCO2eRevenue: $M 1,040Scope 1 Intensity: 7.56 tCO2e/$MShionogi & CoYear: 2024Scope 1: 40,090 tCO2eRevenue: $M 2,873Scope 1 Intensity: 13.95 tCO2e/$MSawai Group HoldingsYear: 2023Scope 1: 19,500 tCO2eRevenue: $M 1,229Scope 1 Intensity: 15.87 tCO2e/$MNihon KohdenYear: 2024Scope 1: 4,155 tCO2eRevenue: $M 1,466Scope 1 Intensity: 2.83 tCO2e/$MAsahi InteccYear: 2024Scope 1: 2,490 tCO2eRevenue: $M 669Scope 1 Intensity: 3.72 tCO2e/$MSundrugYear: 2024Scope 1: 22,197 tCO2eRevenue: $M 4,964Scope 1 Intensity: 4.47 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$MH.U. Group HoldingsYear: 2024Scope 1: 7,367 tCO2eRevenue: $M 1,565Scope 1 Intensity: 4.71 tCO2e/$MMatsukiyoCocokara & CoYear: 2024Scope 1: 3,764 tCO2eRevenue: $M 6,752Scope 1 Intensity: 0.56 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MSuzukenYear: 2024Scope 1: 26,205 tCO2eRevenue: $M 15,759Scope 1 Intensity: 1.66 tCO2e/$MTsuruha HoldingsYear: 2023Scope 1: 3,424 tCO2eRevenue: $M 6,940Scope 1 Intensity: 0.49 tCO2e/$MOtsuka HoldingsYear: 2024Scope 1: 368,733 tCO2eRevenue: $M 14,840Scope 1 Intensity: 24.85 tCO2e/$MMMMedical Data VisionYear: 2024Scope 1: 13 tCO2eRevenue: $M 38Scope 1 Intensity: 0.35 tCO2e/$MSMSYear: 2023Scope 1: 220 tCO2eRevenue: $M 343Scope 1 Intensity: 0.64 tCO2e/$MTsumura & CoYear: 2021Scope 1: 39,385 tCO2eRevenue: $M 1,055Scope 1 Intensity: 37.32 tCO2e/$MNNNippon ShinyakuYear: 2023Scope 1: 4,366 tCO2eRevenue: $M 1,082Scope 1 Intensity: 4.03 tCO2e/$MHikari TsushinYear: 2024Scope 1: 1,102 tCO2eRevenue: $M 3,975Scope 1 Intensity: 0.28 tCO2e/$MAlfresa HoldingsYear: 2025Scope 1: 31,360 tCO2eRevenue: $M 19,746Scope 1 Intensity: 1.59 tCO2e/$MTakeda PharmaceuticalYear: 2024Scope 1: 273,000 tCO2eRevenue: $M 28,155Scope 1 Intensity: 9.70 tCO2e/$MMMMedipal HoldingsYear: 2024Scope 1: 31,081 tCO2eRevenue: $M 23,500Scope 1 Intensity: 1.32 tCO2e/$MKaken PharmaceuticalYear: 2023Scope 1: 11,069 tCO2eRevenue: $M 548Scope 1 Intensity: 20.20 tCO2e/$MSumitomo PharmaYear: 2024Scope 1: 23,101 tCO2eRevenue: $M 2,077Scope 1 Intensity: 11.12 tCO2e/$M

How does Sumitomo Pharma's GHG emissions intensity compare to its peers?

In 2024, Sumitomo Pharma reported a Scope 1 emissions intensity of 11.12 tCO₂e per millions USD. Compared to the peer group median of 4.47, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Sumitomo Pharma rank on GHG emissions intensity within its industry?

In 2024, Sumitomo Pharma ranked 19 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Sumitomo Pharma among the least efficient performers, with one of the highest emissions intensities in its sector.a

Insights into Sumitomo Pharma's Total Carbon Footprint

In 2024, Sumitomo Pharma reported a total carbon footprint of 329,510 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 22.68% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Sumitomo Pharma's total carbon footprint was Scope 3 emissions, accounting for 81.42% of the company's total carbon footprint, followed by Scope 2 emissions at 11.57%.a

Want Full Access to Sumitomo Pharma's GHG Emissions Dataset?
Sign Up